What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?

"CMB reports institutional research funding from AstraZeneca/MedImmune, Amgen and Bristol-Myers Squibb; advisory board membership/consulting for Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Clinical Care Options; Creative Educational Concepts; Curio Science; CVS; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Jazz Pharmaceuticals; Medical Learning Institute; MJH Holdings; Novartis; Novocure; OncLive Clinical Congress Consultants; Sanofi/Regeneron; Seagen; Takeda; Targeted Oncology; Tempus; and membership in a speakers’ bureau for Merck. MCG reports 1) personal financial interests from AstraZeneca, Abion, MSD International GmbH, Bayer, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Incyte, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, Mirati, Daiichi Sankyo, Regeneron, Merck, Blueprint, Jansenn, Sanofi, AbbVie, BeiGenius, Oncohost, Medscape; 2) institutional financial interests from Eli Lilly, MSD, Pfizer (MISP), AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine, Glaxo Smith Kline GSK, Spectrum pharmaceuticals; 3) other interests from AIRC, AIFA, Italian Moh, TRANSCAN, research funding, Horizon 2020. The other authors declare that there are no conflicts of interest."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Hines J. was supported by the National Institute for General Medical Sciences T32 GM07019."